Skip to content

Study · Animal study (in vivo) · rat · 2007

4 results

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF

Gastroenterology20 Dec 2006Cited by 197 (Europe PMC)

PMID17383431 (opens in a new tab)DOI10.1053/j.gastro.2006.12.039 (opens in a new tab)PepBankPUB-17383431
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In PCK rats, octreotide lowered cholangiocyte cAMP within a reported 32%-39% range shared with serum cAMP.

    In plain wordsIn rats with polycystic disease, octreotide lowered cAMP in bile-duct cells.

    Peptide
    Octreotide
    Outcome
    DecreaseCholangiocyte cAMP
    Study

    ratn: not reported in source

    PCK rats with polycystic disease
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo, octreotide lowered cAMP content in cholangiocytes and serum by 32%-39% and inhibited hepatic disease progression, leading to 22%-60% reductions in liver weight, cyst volume, hepatic fibrosis, and mitotic indices.
    1 context sentence
    Summary · context
    The effects of octreotide on hepatic and renal cystogenesis were investigated in PCK rats in vivo.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In PCK rats, octreotide lowered serum cAMP within a reported 32%-39% range shared with cholangiocyte cAMP.

    In plain wordsIn rats with polycystic disease, octreotide lowered blood cAMP.

    Peptide
    Octreotide
    Outcome
    DecreaseSerum cAMP
    Study

    ratn: not reported in source

    PCK rats with polycystic disease
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo, octreotide lowered cAMP content in cholangiocytes and serum by 32%-39% and inhibited hepatic disease progression, leading to 22%-60% reductions in liver weight, cyst volume, hepatic fibrosis, and mitotic indices.
    1 context sentence
    Summary · context
    The effects of octreotide on hepatic and renal cystogenesis were investigated in PCK rats in vivo.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In PCK rats, octreotide reduced liver weight, cyst volume, fibrosis, and mitotic indices within a shared 22%-60% range.

    In plain wordsIn rats with polycystic disease, octreotide reduced liver disease measures.

    Peptide
    Octreotide
    Outcome
    DecreaseHepatic disease progression and structural indices
    Study

    ratn: not reported in source

    PCK rats with polycystic disease
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo, octreotide lowered cAMP content in cholangiocytes and serum by 32%-39% and inhibited hepatic disease progression, leading to 22%-60% reductions in liver weight, cyst volume, hepatic fibrosis, and mitotic indices.
    1 context sentence
    Summary · context
    The effects of octreotide on hepatic and renal cystogenesis were investigated in PCK rats in vivo.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In PCK rats, octreotide produced similar effects on renal disease measures to those observed in the liver.

    In plain wordsIn rats with polycystic disease, octreotide produced similar kidney and liver effects.

    Peptide
    Octreotide
    Outcome
    DecreaseRenal disease measures
    Study

    ratn: not reported in source

    PCK rats with polycystic disease
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar effects were observed in kidneys of PCK rats.
    2 context sentences
    Summary · context
    In vivo, octreotide lowered cAMP content in cholangiocytes and serum by 32%-39% and inhibited hepatic disease progression, leading to 22%-60% reductions in liver weight, cyst volume, hepatic fibrosis, and mitotic indices.
    Summary · context
    The effects of octreotide on hepatic and renal cystogenesis were investigated in PCK rats in vivo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.